Skip to main content
Log in

Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer

  • Short Communication
  • Published:
Oncogene Submit manuscript

Abstract

Colorectal cancer is a major cause of cancer death worldwide. A number of key oncogenes and tumor suppressor genes have been proposed to drive progression from healthy colonic epithelia to malignant tumors, including members of the Wnt/β-catenin pathway. Recently, CpG island promoter hypermethylation was shown to cause inactivation of two extracellular Wnt inhibitors in colon cancer: secreted frizzled-related proteins (sFRPs) and Wnt inhibitory factor-1 (WIF-1). Here, we show for the first time that another extracellular Wnt inhibitor, the DICKKOPF-1 (DKK-1) gene, is transcriptionally silenced by CpG island promoter hypermethylation in colon cancer cell lines (n=9), whereas treatment with the DNA-demethylating agent 5-aza-2-deoxycytidine restored DKK-1 expression. Restoration of DKK-1 function in non-expressing cells bearing a truncated APC (Adenomatous Polyposis Coli) gene had no effect on β-catenin/T-cell factor-dependent transcription, but induced tumor suppressor-like features such as reduced colony formation density and tumor growth inhibition in nude mice. These results suggest additional functions for DKK-1 other than inhibiting canonical Wnt signaling. In primary colorectal tumors, DKK-1 was found hypermethylated in 17% (nine of 54) of cases. Furthermore, while for both SFRP-1 and WIF-1 methylation-associated silencing occurred across the whole spectrum of colorectal tumorigenesis, DKK-1 promoter was selectively hypermethylated in advanced colorectal neoplasms (Duke's C and D tumors).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  • Alaminos M, Dávalos V, Ropero S, Setién F, Paz MF, Herranz M et al. (2005). Cancer Res 65: 2565–2571.

  • Bafico A, Liu G, Goldin L, Harris V, Aaronson SA . (2004). Cancer Cell 6: 497–506.

  • Bafico A, Liu G, Yaniv A, Gazit A, Aaronson SA . (2001). Nat Cell Biol 3: 683–686.

  • Ballestar E, Esteller M . (2002). Carcinogenesis 23: 1103–1119.

  • Ballestar E, Paz MF, Valle L, Wei S, Fraga MF, Espada J et al. (2003). EMBO J 22: 6335–6345.

  • Chamorro MN, Schwartz DR, Vonica A, Brivanlou AH, Cho KR, Varmus HE . (2005). EMBO J 24: 73–84.

  • Fearon ER, Vogelstein B . (1990). Cell 61: 759–767.

  • Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G et al. (2005). Nat Genet 37: 391–400.

  • Fraga MF, Herranz M, Espada J, Ballestar E, Paz MF, Ropero S et al. (2004). Cancer Res 64: 5527–5534.

  • Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK . (2003). Oncologist 8: 541–552.

  • González-Sancho JM, Aguilera O, García JM, Pendás-Franco N, Peña C, Cal S et al. (2005). Oncogene 24: 1098–1103.

  • González-Sancho JM, Brennan KR, Castelo-Soccio LA, Brown AMC . (2004). Mol Cell Biol 24: 4757–4768.

  • He B, Reguart N, You L, Mazieres J, Xu Z, Lee AY et al. (2005). Oncogene 24: 3054–3058.

  • Kawano Y, Kypta R . (2003). J Cell Sci 116: 2627–2634.

  • Kinzler KW, Vogelstein B . (1996). Cell 87: 159–170.

  • Kuhnert F, Davis CR, Wang HT, Chu P, Lee M, Yuan J et al. (2004). Proc Natl Acad Sci USA 101: 266–271.

  • Lee AY, He B, You L, Xu Z, Mazieres J, Reguart N et al. (2004). Biochem Biophys Res Commun 323: 1246–1250.

  • Maeda K, Kawakami K, Ishida Y, Ishiguro K, Omura K, Watanabe G . (2003). Oncol Rep 10: 935–938.

  • Mao B, Wu W, Davidson G, Marhold J, Li M, Mechler BM et al. (2002). Nature 417: 664–667.

  • Mao B, Wu W, Li Y, Hoppe D, Stannek P, Glinka A et al. (2001). Nature 411: 321–325.

  • Mazieres J, He B, You L, Xu Z, Lee AY, Mikami I et al. (2004). Cancer Res 64: 4717–4720.

  • Mikheev AM, Mikheeva SA, Liu B, Cohen P, Zarbl H . (2004). Carcinogenesis 25: 47–59.

  • Miller JR . (2002). Genome Biol 3: 1–15.

  • Niida A, Hiroko T, Kasai M, Furukawa Y, Nakamura Y, Suzuki Y et al. (2004). Oncogene 23: 8520–8526.

  • Pinto D, Gregorieff A, Begthel H, Clevers H . (2003). Genes Dev 17: 1709–1713.

  • Sancho E, Batlle E, Clevers H . (2004). Annu Rev Cell Dev Biol 20: 695–723.

  • Semenov MV, Tamai K, Brott BK, Kuhl M, Sokol S, He X . (2001). Curr Biol 11: R92–R95.

  • Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van Engeland M, Weijenberg MP et al. (2002). Nat Genet 31: 141–149.

  • Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, Chen WD et al. (2004). Nat Genet 36: 417–422.

  • Zou HZ, Yu BM, Wang ZW, Sun JY, Cang H, Gao F et al. (2002). J Clin Cancer Res 8: 188–191.

Download references

Acknowledgements

We thank Esteban Fernando Setién, Paula García, Sara Casado and Diego Navarro for excellent technical assistance. Grant support: Ministerio de Educación y Ciencia (SAF2004-01015) of Spain, Fundación de Investigación Médica Mutua Madrileña.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M Esteller.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aguilera, O., Fraga, M., Ballestar, E. et al. Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer. Oncogene 25, 4116–4121 (2006). https://doi.org/10.1038/sj.onc.1209439

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1209439

  • Springer Nature Limited

Keywords

This article is cited by

Navigation